| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
55,516 |
50,476 |
$4.06M |
| 76830 |
Ultrasound, transvaginal |
42,176 |
40,967 |
$3.51M |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
30,478 |
25,782 |
$2.82M |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
33,557 |
26,621 |
$2.49M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
37,910 |
29,497 |
$1.90M |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
17,335 |
17,307 |
$1.61M |
| 76820 |
|
39,140 |
24,395 |
$1.37M |
| 58558 |
|
994 |
993 |
$1.22M |
| 76819 |
Fetal biophysical profile; without non-stress testing |
14,987 |
11,019 |
$1.17M |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
25,018 |
24,548 |
$1.06M |
| 76818 |
|
9,680 |
5,283 |
$986K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
12,480 |
10,396 |
$958K |
| 99385 |
|
7,811 |
7,810 |
$819K |
| 81513 |
|
6,518 |
6,441 |
$676K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
6,532 |
6,524 |
$665K |
| 76801 |
|
7,780 |
6,059 |
$624K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
23,864 |
23,644 |
$562K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
23,849 |
23,630 |
$560K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
21,911 |
21,711 |
$524K |
| 59400 |
Routine obstetric care including antepartum care, vaginal delivery, and postpartum care |
129 |
129 |
$329K |
| 81025 |
|
75,566 |
71,084 |
$312K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,523 |
2,519 |
$308K |
| 76813 |
|
2,820 |
2,816 |
$301K |
| 99386 |
|
2,034 |
2,033 |
$245K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
9,189 |
9,177 |
$240K |
| 59426 |
|
215 |
215 |
$214K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,090 |
2,089 |
$210K |
| 59430 |
|
740 |
739 |
$191K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
9,947 |
9,923 |
$189K |
| 76376 |
|
10,057 |
9,901 |
$155K |
| 81002 |
|
79,039 |
74,756 |
$152K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,187 |
1,151 |
$116K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,617 |
1,543 |
$105K |
| 76857 |
|
2,887 |
2,841 |
$91K |
| 57454 |
|
549 |
548 |
$90K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,525 |
1,520 |
$88K |
| 87481 |
|
3,193 |
3,160 |
$76K |
| 00952 |
|
790 |
789 |
$69K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
386 |
386 |
$59K |
| 84144 |
|
3,004 |
2,689 |
$54K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,033 |
963 |
$44K |
| 86780 |
|
3,762 |
3,731 |
$40K |
| 82670 |
|
1,664 |
1,657 |
$40K |
| 59840 |
|
158 |
158 |
$39K |
| 36415 |
Collection of venous blood by venipuncture |
49,507 |
43,482 |
$38K |
| 84702 |
|
3,282 |
2,916 |
$38K |
| 82626 |
|
1,620 |
1,613 |
$35K |
| 59510 |
|
12 |
12 |
$34K |
| 84146 |
|
1,649 |
1,641 |
$28K |
| 83001 |
|
1,631 |
1,623 |
$27K |
| 83002 |
|
1,573 |
1,565 |
$26K |
| 86703 |
|
2,209 |
2,191 |
$25K |
| 88342 |
|
600 |
598 |
$25K |
| 84439 |
|
3,043 |
2,933 |
$24K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,570 |
2,471 |
$24K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
335 |
334 |
$22K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
228 |
228 |
$21K |
| 88341 |
|
618 |
616 |
$21K |
| 59409 |
Vaginal delivery only (with or without episiotomy and/or forceps) |
27 |
27 |
$20K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
952 |
914 |
$19K |
| 01966 |
|
195 |
195 |
$18K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,262 |
1,256 |
$16K |
| 80053 |
Comprehensive metabolic panel |
1,578 |
1,532 |
$14K |
| 88141 |
|
809 |
809 |
$14K |
| 87625 |
|
455 |
454 |
$13K |
| 84481 |
|
1,317 |
1,311 |
$12K |
| 76641 |
|
152 |
123 |
$12K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
179 |
156 |
$12K |
| 99384 |
|
101 |
101 |
$11K |
| 86696 |
|
841 |
837 |
$11K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
943 |
942 |
$11K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,873 |
2,775 |
$10K |
| 93975 |
|
48 |
47 |
$10K |
| 86762 |
|
797 |
784 |
$9K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
60 |
60 |
$9K |
| 87563 |
|
370 |
364 |
$8K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
225 |
225 |
$8K |
| 86765 |
|
703 |
691 |
$7K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
239 |
238 |
$7K |
| 58301 |
|
63 |
63 |
$7K |
| 82607 |
|
583 |
583 |
$6K |
| 86706 |
|
748 |
740 |
$6K |
| 93976 |
|
162 |
161 |
$6K |
| 86735 |
|
701 |
689 |
$6K |
| 86787 |
|
538 |
530 |
$5K |
| 80074 |
|
190 |
188 |
$4K |
| 86704 |
|
456 |
452 |
$4K |
| 82746 |
|
373 |
373 |
$4K |
| 80061 |
Lipid panel |
569 |
569 |
$4K |
| 76821 |
|
49 |
36 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
2,184 |
2,173 |
$4K |
| 86708 |
|
361 |
359 |
$3K |
| 84480 |
|
502 |
494 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
601 |
585 |
$3K |
| 86777 |
|
220 |
217 |
$3K |
| 00940 |
|
28 |
27 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,472 |
1,465 |
$2K |
| 0012A |
|
66 |
65 |
$2K |
| 0011A |
|
62 |
62 |
$2K |
| 80050 |
General health panel |
101 |
101 |
$2K |
| 88304 |
|
163 |
162 |
$2K |
| 58300 |
|
25 |
25 |
$2K |
| 84403 |
|
62 |
62 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
36 |
36 |
$1K |
| 82950 |
|
287 |
286 |
$1K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
36 |
36 |
$1K |
| 83540 |
|
202 |
201 |
$929.85 |
| 83550 |
|
183 |
182 |
$902.63 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,319 |
1,316 |
$902.01 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
12 |
12 |
$881.42 |
| 86695 |
|
198 |
198 |
$793.09 |
| 81003 |
|
456 |
450 |
$702.31 |
| S0190 |
Mifepristone, oral, 200 mg |
13 |
13 |
$516.05 |
| 82947 |
|
137 |
135 |
$472.23 |
| 84436 |
|
82 |
82 |
$319.08 |
| 82040 |
|
43 |
43 |
$188.69 |
| 82951 |
|
13 |
13 |
$117.87 |
| 99000 |
|
31,146 |
30,439 |
$85.33 |
| 83615 |
|
16 |
16 |
$73.23 |
| 84479 |
|
48 |
48 |
$67.44 |
| 84550 |
|
16 |
16 |
$61.26 |
| 82465 |
|
12 |
12 |
$47.85 |
| 84270 |
|
66 |
66 |
$31.77 |
| 91301 |
|
88 |
87 |
$0.25 |